DermaFocus, a leader in regenerative aesthetic solutions, is pleased to announce a strategic partnership with InMode, a global innovator in energy-based technology. This collaboration marks a significant step forward in expanding the distribution of Purasomes, a unique exosome and growth-factor-based range for skin and hair regeneration.
The products include:
Each of the Purasomes products contains AMPLEX Plus – a patented technology that has been created using secretomes, which combines the action of 20 billion exosomes, 20 growth factors and other beneficial properties from ethically sourced bovine colostrum.
The partnership
Through this partnership, InMode will integrate Purasomes into its portfolio of innovative energy-based aesthetic solutions, which include the Morpheus8 and Fractora radiofrequency microneedling devices, the Forma RF, the Lumecca IPL technology and the NEW InMode Allure.
The regenerative properties of the Purasomes range will complement the results of InMode’s energy-based treatments, providing practitioners with a powerful tool to optimise patient outcomes.
The impact
This partnership aligns with both companies' mission to advance the field of regenerative medical aesthetics by delivering scientifically backed, results-driven solutions. InMode’s robust presence in the UK aesthetics market ensures that Purasomes will reach more medical professionals and patients seeking non-invasive, high-efficacy regenerative solutions.
“We are thrilled to partner with InMode, a company that shares our commitment to innovation and excellence in aesthetic medicine,” said Milad Bemana, executive director of DermaFocus. “By combining our expertise in regenerative treatments with InMode’s extensive distribution network and cutting-edge technology, we are poised to bring the transformative benefits of Purasomes to a wider audience.”
Victoria Voysey, managing director of InMode UK added, “InMode is dedicated to providing best-in-class technologies that empower practitioners and enhance patient results. The addition of Purasomes to our product offering reinforces our commitment to innovation in aesthetics, and we are excited about the impact this collaboration will have on patients in the UK.”